Anthony J. Hall

Anthony J. Hall

Auto-generated profile, based on publicly available information

Anthony J. Hall

Department of Ophthalmology Alfred Hospital Melbourne Victoria Australia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2022 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
ZCZelia K. Chiu
Zelia K. Chiu
JGJonathan Ks. Goh
Jonathan Ks. Goh
CLCecilia Ling
Cecilia Ling
MLMing-Lee Lin
Ming-Lee Lin
AHAnthony J. Hall
Anthony J. Hall
Four cases of ibrutinib-related uveitis are presented, which are to the best of our knowledge the first in the literature. Possible mechanisms of ibrutinib-mediated uveitis are explored. Case 1 is a 60-year-old female who had been stable on 1 year of ibrutinib for chronic lymphocytic leukaemia. She was diagnosed with ibrutinib-related uveitis, which responded well to topical steroids. Case 2 is a 63-year-old male diagnosed with uveitis after 2 years of ibrutinib treatment for chronic lymphocytic leukaemia. He responded well to topical and oral steroids; however, he continued to have uveitis relapses after weaning steroids. Case 3 is a 69-year-old male diagnosed with uveitis after 18 months of ibrutinib treatment. He was trialed on topical and intravenous steroids, and restarted ibrutinib without worsening of symptoms. Case 4 is a 66-year-old female who developed uveitis after being stable on ibrutinib for 3 years. She responded well to topical steroids. Inflammatory complications of tyrosine kinase inhibitors are well described. While ibrutinib, and other kinase inhibitors, are generally well-tolerated, there are increasing reports of ocular toxicities, including uveitis. It is recommended to monitor patients for potential ocular adverse effects and facilitate rapid ophthalmologic assessment.

1 January 2017 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
MCMiguel S. Cabalag
Miguel S. Cabalag
JWJason Wasiak
Jason Wasiak
QSQuaderi Syed
Quaderi Syed
EPEldho Paul
Eldho Paul
AHAnthony J. Hall
Anthony J. Hall
Heather ClelandHeather Cleland
Heather Cleland
The surgical management of severe ocular burns is challenging and often associated with variable long-term outcome. The aims of this study were to analyze the clinical course of these injuries and determine the factors associated with the need for surgery. A retrospective medical records review was conducted for patients admitted to the Victorian Adult Burns Services, with ocular burns, from January 2000 to January 2010. One hundred and twenty-nine patients were admitted with ocular burns, of which 17 (13.2%) required surgery. The most common indication for surgery was ectropion (n = 9) and the most frequent procedure was full-thickness skin grafts to the eyelids (n = 10). Almost all patients managed surgically developed late ocular complications, the most frequent being visual loss and recurrent ectropion (n = 7 each). Patients undergoing surgery had a longer length of hospital stay (median [interquartile range] 40 [12–90] vs 12 [4–29.5] days; P = .004) and larger TBSA burned (median [interquartile range] 20 [10–60] vs 8 [4–20]; P = .011). Factors associated with the need for surgery included flame burns, periorbital edema, visual loss on presentation, increasing severity of eyelid and facial burns, severe corneal injury, as well as lagophthalmos, ectropion, and microbial keratitis (P < .05). Although only a minority required surgery, these patients often require multiple procedures and develop long-term ocular morbidity.

22 October 2025 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
ESEzann Siebert
Ezann Siebert
VMVerity Moynihan
Verity Moynihan
NANoha Ali
Noha Ali
AHAnthony Hall
Anthony Hall
PHPeter Heydon
Peter Heydon
JRJosephine Richards
Josephine Richards

1 June 2017 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
EKEnis D. Kocak
Enis D. Kocak
BWBob Z. Wang
Bob Z. Wang
AHAnthony J. Hall
Anthony J. Hall
To report a case of bilateral acute anterior uveitis in an adult female occurring following the administration of intravenous immunoglobulin (IVIG). A 44-year-old female patient was commenced on IVIG following presentation to hospital with upper limb neuropathic pain. Within two days, she developed bilateral red, painful photophobic eyes. Examination revealed bilateral acute anterior uveitis and IVIG was ceased. Investigations for autoimmune or infective causes for the uveitis were unremarkable. Complete resolution of the uveitis was achieved with topical corticosteroids and cessation of IVIG. Clinicians should be aware of the possibility of uveitis as an adverse effect of IVIG. Early identification of the offending medication and its cessation in this case were associated with a good visual prognosis.

3 November 2020 in Journal of Ophthalmic Inflammation and Infection
Verified
Journal Article
Open access
PDF file
WLWen-Shen Lee
Wen-Shen Lee
SPShaun Parsons
Shaun Parsons
DCDean Cugley
Dean Cugley
SRSophie Rogers
Sophie Rogers
LLLyndell L. Lim
Lyndell L. Lim
AHAnthony Hall
Anthony Hall
Background: To investigate a possible association between glaucoma and the use of anti-retroviral therapy (ART) for HIV in the Australian population.Methods: A retrospective review of Australian Pharmaceutical Benefits Scheme data was undertaken from July 2012 to December 2016, inclusive. Three patient groups were compared: those on both topical intraocular pressure (IOP) -lowering medication and ART, those on ART only, and those on IOP-lowering medication only, using the 2016 Australian resident population to estimate prevalence. Odds ratios (95% confidence intervals, [CI]) with Fishers exact test forpvalues were calculated stratified by age and gender.Results: The number of prescriptions for topical glaucoma medications in the general Australian population increased progressively by age with a peak prevalence in those aged 80 years and above. Prevalence of ART was highest in males aged 40–49 and 50–59 years (0.41% [CI 0.40, 0.42] and 0.44% [CI 0.43, 0.45], respectively). Our analysis identified an increase in the prescription of IOP-lowering medication in males on ART aged 30–39 (OR 2.23 [CI 1.32, 3.75],p = 0.007) and 40–49 (OR 1.86 [CI 1.42, 2.43],p < 0.001), compared to those not on ART. There were no statistically significant increased odds for females or males aged 50 years or more.Conclusion: Compared with the known increase in glaucoma prevalence with age in the general Australian population, a statistically significant increased prevalence in use of IOP-lowering medications was found in males on ART aged 30–49 years. The mechanism for this is yet to be determined, but possible causes include sequelae of HIV infection, a drug-induced side effect, or increased medical surveillance.

10 January 2023 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
SPSachin Phakey
Sachin Phakey
SRSophie L. Rogers
Sophie L. Rogers
AHAnthony J. Hall
Anthony J. Hall
LLLyndell Lim
Lyndell Lim
Introduction Zostavax, the live-attenuated vaccine used to prevent herpes zoster (HZ), has been available to individuals aged 70 and 71–79 years (phased catch-up) via Australia’s National Immunisation Program (NIP) since 2016. There are limited data characterising the incidence of HZ at the level of the Australian population. National prescription data for antivirals used to treat HZ may be used as a proxy for HZ incidence. We aimed to examine trends in antiviral prescriptions supplied for the treatment of HZ in Australia pre- and post-2016, and to assess whether Zostavax’s inclusion on the NIP correlated with a reduction in HZ antiviral prescription rates. Methods Using the Australian Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme prescribing data, we analysed antiviral prescriptions supplied for the treatment of HZ Australia-wide between 1994 and 2019. Annual prescription rates were calculated, and trends and changes in HZ antiviral use were explored descriptively and using Poisson models. Results HZ antiviral prescription rates increased 2.6-fold (160%) between 1995 and 2015 [25.4 (95% CI 25.2, 25.6) and 65.3 (95% CI 64.9, 65.6) prescriptions per 10,000 people, respectively], and then decreased 0.45-fold (55%) between 2016 and 2018 [60.9 (95% CI 60.6, 61.2) and 27.5 (95% CI 27.3, 27.9) prescriptions per 10,000 people, respectively]. The prescription rate for the antiviral famciclovir restricted specifically for treating HZ in immunocompromised individuals increased 8.5-fold (750%) between 2006 (year first listed) and 2019 [0.3 (95% CI 0.3, 0.3) and 2.5 (95% CI 2.4, 2.6) prescriptions per 10,000 people, respectively]. Conclusion The introduction of the live-attenuated HZ vaccine on Australia’s formal national vaccination program was associated with a reduction in HZ antiviral prescription rates within the Australian population. The data suggest that the introduction of Shingrix, the non-live subunit zoster vaccine, may also be associated with a similar reduction in HZ antiviral prescriptions used to treat the immunocompromised, as well as the general population, given its accepted greater efficacy over Zostavax.